BioNTech SE
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BNTX research report →
Range $96 – $140
Price Chart
About the company
BioNTech SE is a biotechnology firm dedicated to the research, development, and marketing of immunotherapies for oncology and a spectrum of infectious diseases. Its diverse product pipeline features several FixVac candidates, including BNT111, currently undergoing Phase II clinical trials for advanced melanoma; BNT112, in Phase I/IIa development for prostate cancer; BNT113, progressing through Phase II for HPV-positive head and neck cancers; BNT114, in Phase I for triple-negative breast cancer; BNT115, also in Phase I for ovarian cancer; and BNT116, a preclinical asset targeting non-small cell lung cancer. Further expanding its oncology focus, BioNTech is advancing neoantigen-specific immunotherapies like Autogene cevumeran (BNT122), which is in Phase II trials for first-line melanoma and Phase 1a/1b trials for multiple solid tumors.
- CEO
- Ugur Sahin
- IPO
- 2019
- Employees
- 7,807
- HQ
- Mainz, RP, DE
AI snapshot
Six angles, distilled from the data.
The stock is in a medium-term downtrend, trading below both the 50-day and 200-day moving averages. It sits well off the 52-week high of 124 and closer to the 52-week low of 79.52, which keeps the chart in a repair phase rather than a confirmed uptrend.
Street sentiment stays constructive, with a Buy consensus and an average target of 118.57 versus the current share price. Recent calls have leaned toward modest target trims rather than outright downgrades, which suggests analysts still see upside but are tempering expectations.
The latest quarter delivered a sharp EPS beat, with 1.94 versus 0.85 expected, but the broader pattern remains uneven at 3 beats in the last 8 quarters. Next-year EPS is still projected negative at -4.726, so shareholders should watch whether revenue and margin trends stabilize after the recent surprise.
Insider activity is dominated by repeated open-market selling from CEO and 10% owner Ugur Sahin, with 15 sales and no buys. The pattern points to persistent distribution rather than opportunistic accumulation, and there is no offsetting discretionary buying to soften the signal.
Profitability remains weak despite strong gross margin, with gross margin at 76.7% but operating margin at -55.45% and net margin at -60.87%. Revenue fell 15.1% year over year, yet the balance sheet is strong with $14.83 billion in cash and equivalents against $267.3 million of debt.
BioNTech stands out for a large cash position and pipeline breadth, but it still trails profitable biotech peers on earnings power and margin discipline. The valuation remains elevated for a company with negative EPS, even with a consensus target above the current price.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $20.07B
- P/E
- -12.92
- PEG
- 0.13
- P/S
- 7.82
- P/B
- 1.07
- EV/EBITDA
- -21.10
- Div Yield
- 0.00%
- Gross Margin
- 67.86%
- Op Margin
- -63.12%
- Net Margin
- -61.53%
- ROE
- -8.09%
- ROIC
- -8.26%
Latest fiscal year · YoY change
- Revenue
- $2.76B+0.2%
- Gross Profit
- $2.14B-3.2%
- Op Income
- $-623,865,983
- Net Income
- $-1,091,261,192-64.0%
- EPS
- $-4.51-62.8%
- OCF Growth
- +110.9%
- FCF Growth
- +210.3%
- 52W High
- $124.00
- 52W Low
- $79.52
- 50D MA
- $91.83
- 200D MA
- $95.21
- Beta
- 1.33
- RSI (14)
- 32
- Avg Volume
- 1.10M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
BioNTech said it is making progress toward a diversified oncology pipeline, with encouraging lung-cancer data, a revenue beat on BMS collaboration income, and a higher full-year revenue outlook, while several late-stage programs remain event-driven and still need confirmation.· November 3, 2026
- Gotistobart showed strong survival data in squamous NSCLC, with median overall survival of 18.5 months versus 10 months on docetaxel and a hazard ratio of 0.56.
- Pumitamig is becoming the backbone of BioNTech’s combo strategy, with new collaboration work, multiple registrational programs, and phase III planning across lung and breast cancer.
- The company raised full-year 2026 revenue guidance to EUR 1.7 billion-EUR 1.9 billion after a strong quarter, while keeping adjusted R&D and SG&A guidance unchanged.
- T-Pam met its primary endpoint, but management said the benefit looked modest and the safety profile included a higher ILD rate, with severe and fatal cases in a small proportion of patients.
- BioNTech ended the quarter with EUR 16.2 billion in cash equivalents and security investments and repurchased about 5 million shares through September 30.
Third-quarter 2026 revenue was EUR 1.3 billion, versus EUR 1.5 billion in the prior-year third quarter. Adjusted R&D expense rose to EUR 579 million from EUR 479 million, and SG&A was EUR 179 million versus EUR 149 million last year. On an IFRS basis, R&D expense was EUR 748 million, including EUR 169 million of impairment losses. Year to date, revenue was EUR 1.5 billion versus EUR 2.0 billion, adjusted R&D was EUR 1.6 billion versus EUR 1.5 billion, and adjusted SG&A was EUR 527 million versus EUR 407 million. Cash equivalents and security investments were EUR 16.2 billion at quarter-end. BioNTech raised full-year 2026 revenue guidance to EUR 1.7 billion-EUR 1.9 billion; adjusted R&D guidance stays at EUR 2.0 billion-EUR 2.3 billion and SG&A at EUR 700 million-EUR 800 million.
Uğur Şahin framed the quarter as continued execution against 2026 strategic milestones, centered on late-stage oncology development and a shift toward a diversified multi-product company by 2030. He highlighted gotistobart, the Gilead combination collaboration for pumitamig, and early combination data as evidence that BioNTech’s tumor-centric strategy is gaining traction. His tone was confident and reflective, as he also used the call to mark his final earnings call and point to a planned leadership transition to Guido Oelkers.
Ramón Zapata focused on the quarter’s financial resilience and capital allocation discipline. He cited EUR 1.3 billion in Q3 revenue, the EUR 613 million contribution from BMS-related pumitamig partnership revenue, EUR 16.2 billion of cash equivalents and security investments, and the decision to raise full-year revenue guidance to EUR 1.7 billion-EUR 1.9 billion while holding expense guidance steady. He also stressed the share buyback program, approximately 5 million shares repurchased through September 30, the divestiture of JPT Peptide Technologies, manufacturing footprint consolidation, and the plan to integrate InstaDeep into core operations; on Roche/Genentech, he said future R&D costs for the collaboration will shift to Roche/Genentech under the exercised option, with BioNTech moving to royalty-based economics.
Analysts pressed on whether gotistobart’s first interim or second interim matters more, and management said the first readout is early and they would not be disappointed if no clear signal emerges; they expect to comment either way when it arrives. Questions also focused on the Roche/Genentech mRNA collaboration, where management said the change is mainly a resource-allocation decision and does not signal reduced commitment to mRNA, especially PDAC. There were repeated questions on pumitamig combinations, TROP2 ADC strategy, and read-through from China to global studies; management emphasized the approach is data-driven, that multiple ADCs remain under evaluation, and that they do see regional-to-global translation in this class. On T-Pam, management said it will review the totality of data with DualityBio before deciding next steps and potential BLA submission.
The positive case from the call is that BioNTech has multiple late-stage shots on goal and some of the most important data looked encouraging, especially gotistobart and pumitamig combinations. Management sounded confident that the company’s lung cancer franchise, partnership model, and cash position can support a path to first approvals and a multi-product business by 2030.
The main risks are that several programs are still early, event-driven, or awaiting confirmation, and management repeatedly said timing can move. T-Pam’s benefit was described as modest with a higher ILD rate including severe and fatal events in a small proportion of patients, while the BNT113 trial missed its first PFS endpoint and will now rely on OS. BioNTech also acknowledged no detailed regulatory discussion yet for gotistobart and said the first interim is early enough that a clear signal is not assured.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.6%
- Shares Outstanding
- 247.93M
- Float Shares
- 246.87M
of shares held by institutions
320 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for BNTX, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Val HoyleHouse · OR04 | Sell | Aug 7, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Sep 3, 24 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Aug 30, 24 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Apr 15, 24 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Mar 14, 24 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Dec 5, 23 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Dec 6, 23 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Dec 7, 23 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 20, 22 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 9.80M | ▲ 2.23M |
| Primecap Management Co | 3.75M | ▼ 19.54K |
| Dodge & Cox | 3.69M | ▲ 10.20K |
| T. Rowe Price Investment Management, Inc. | 2.07M | ▼ 3.79M |
| Blackrock, Inc. | 1.83M | ▼ 20.00K |
| Bnp Paribas Financial Markets | 1.28M | ▼ 37.53K |
| Temasek Holdings (Private) Ltd | 1.24M | ▼ 270.20K |
| Logos Global Management LP | 1.01M | ▲ 1.01M |
| First Trust Advisors LP | 996.31K | ▲ 204.84K |
| Ubs Am, A Distinct Business Unit Of Ubs Asset Management Americas LLC | 744.20K | ▼ 39.80K |
| Davern Capital Partners, LP | 682.15K | ▼ 72.40K |
| Gsk PLC | 668.53K | ▼ 221.30K |
Held by 256 ETFs
Biggest fund positions in BNTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 8, 26 | Sahin Ugur | sell | 27,000 |
| Oct 9, 26 | Sahin Ugur | sell | 36,209 |
| Oct 7, 26 | Sahin Ugur | sell | 24,000 |
| Oct 5, 26 | Sahin Ugur | sell | 72,000 |
| Oct 6, 26 | Sahin Ugur | sell | 21,000 |
| Oct 1, 26 | Sahin Ugur | sell | 17,000 |
| Oct 2, 26 | Sahin Ugur | sell | 17,000 |
| Sep 29, 26 | Sahin Ugur | sell | 34,000 |
| Sep 30, 26 | Sahin Ugur | sell | 32,000 |
| Sep 25, 26 | Sahin Ugur | sell | 27,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BNTX coverage
Recent articles, reports, and earnings notes.

BioNTech (BNTX): Oncology Pipeline Upside vs. Earnings Drag
BioNTech is transitioning from COVID vaccine revenue to a late-stage oncology pipeline, with strong clinical signals but continued earnings pressure. The balance sheet gives it time, but execution risk remains high.

BioNTech (BNTX): Oncology Pipeline Drives the Turnaround
BioNTech is moving from fading COVID-19 vaccine revenue to a multi-product oncology pipeline, but near-term earnings remain weak. Its cash-rich balance sheet supports the transition, yet the stock still depends on late-stage clinical execution.

BioNTech SE (BNTX) jumps 16.9% after-hours on pipeline re-rating
BioNTech SE (BNTX) jumps in after-hours trading as investors reprice its oncology pipeline following the Aug. 4 update. The move reflects renewed optimism around late-stage trials and analyst support, but it remains an extended-hours signal that still needs confirmation in regular trading.
Want a deeper read on BNTX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Moderna vs. BioNTech: Why Only 1 Is a Buy Heading Into 2027
fool.com · Nov 20
BioNTech May Be the Next Moderna. Even if it Isn't, the Stock Is a Buy.
barrons.com · Nov 12
BioNTech vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
fool.com · Nov 11
BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era.
fool.com · Nov 9
Moderna Climbs 5% as Surprise Profit and Raised Outlook Beat Forecasts; Pfizer Dips, BioNTech Edges Higher
247wallst.com · Nov 6
Axsome Therapeutics vs. BioNTech: Which Healthcare Stock Is a Better Buy for 2027?
fool.com · Nov 5
BioNTech Q3: Bristol Myers Revenue Masks A Narrowing Oncology Bet (Rating Downgrade)
seekingalpha.com · Nov 4
BioNTech SE (BNTX) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 18, 2026 · Live quote · Not investment advice